Bafisontamab is under clinical development by EpimAb Biotherapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bafisontamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bafisontamab (EMB-01) is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer, gastric cancer, liver cancer, bile duct cancer (cholangiocarcinoma) and hepatocellular cancer. The drug candidate is a bi-specific monoclonal antibody. The drug candidate is developed based on FIT-Ig (Fabs-In-Tandem Immunoglobulin) technology. The drug candidate acts by targeting epidermal growth factor receptor and hepatocyte growth factor receptor (cMET).
EpimAb Biotherapeutics overview
EpimAb Biotherapeutics (EpimAb) is an independent biopharmaceutical research and development company that develops bispecific antibody therapeutics with a focus on immune-oncology. Its lead product candidate EMB-01, which is in preclinical development, is a bispecific antibody that targets epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET). EpimAb harnesses Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology, which integrates the functions of two parental antibodies into one single molecule, to develop its product portfolio. The company works in collaboration with Kymab, Innovent Biologics, and Zhejiang Teruisi Biopharmaceutical to develop bispecific antibody programs. EpimAb is headquartered in Shanghai, China.
For a complete picture of Bafisontamab’s drug-specific PTSR and LoA scores, buy the report here.